HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group).

Abstract
CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin. Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.
AuthorsR Nitschke, C Pratt, M Harris, J Krischer, T J Vietti, H Grier, W Kamps, S Toledano
JournalInvestigational new drugs (Invest New Drugs) Vol. 10 Issue 2 Pg. 93-6 (Jul 1992) ISSN: 0167-6997 [Print] United States
PMID1323551 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • iproplatin
Topics
  • Adolescent
  • Adult
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Child
  • Drug Evaluation
  • Humans
  • Neoplasms (drug therapy)
  • Neoplasms, Germ Cell and Embryonal (drug therapy)
  • Neuroblastoma (drug therapy)
  • Organoplatinum Compounds (adverse effects, therapeutic use)
  • Recurrence
  • Sarcoma (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: